In bladder carcinoma, FXR inhibits cancer cell migration, adhesion, and angiogenesis through proteasome degradation, VEGF reduction, AMPK activation, and cholesterol biosynthesis inhibition [137,138]. Here, NR1H4 is linked to urinary bladder carcinoma.